SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014.
Employing Icon’s Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.
Help employers find you! Check out all the jobs and post your resume.
Employing Icon’s Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.
Help employers find you! Check out all the jobs and post your resume.
